FAQs

Why does early diagnosis of Axial Spondyloarthritis matter?

• Early definitive diagnosis facilitates a treatment plan for the best patient outcome

• Controlling chronic inflammatory disease early results in less progression, the best opportunity for remission

• The above features reduce health care costs substantially

Why are Lipocalin2 (LCN2) and Lipocalin2-Matrix Metalloprotease 9 (LCN2-MMP9) biomarkers better alternatives for diagnosing and revealing hidden parts of inflammation than the current practice?

LCN2 and LCN2-MMP9 give KeyIn-1 a major scientific advantage because they come directly from the actual tissues involved in chronic inflammatory diseases rather than from the liver, like ESR and CRP. This means they capture direct biological activity at the disease site, including early inflammatory changes and the balance between tissue damage and repair. LCN2 rises when local cells, such as adipose and other adjacent cells, respond to injury, while the protease-active  LCN2-MMP9 forms only in the oxidizing environment of active inflammation, where tissue is being broken down and rebuilt. These molecules enter the bloodstream intact in distinct patterns that differ between healthy individuals and patients, creating a clear, measurable molecular signal that current markers consistently miss. As a result, LCN2 and LCN2-MMP9 enable KeyIn-1 to detect hidden inflammation earlier, track treatment impact more precisely, and provide clinicians with a level of diagnostic confidence that standard blood tests cannot deliver, making this biomarker platform both scientifically differentiated and commercially compelling.

How does KeyIn-1 improve early diagnosis and inflammation assessment of Axial Spondyloarthritis? 

Using a blood sample as input, KeyIn-1 integrates the biomarkers LCN2, the LCN2–MMP9 complex, and AI-based analytics to generate a comprehensive biomarker profile. As a result, KeyIn-1 makes inflammation and repair measurable, actionable, and trackable from a simple blood test, while revealing and quantifying clinically important hidden inflammation signals.

What hidden inflammation signals can be measured by KeyIn-1 that were not previously detectable?

• Inflammation propensity/intensity

• Repair propensity/intensity

• Fluctuation probability

• Inflammation–repair balance

Can KeyIn-1 be used for different chronic inflammatory diseases? 

It is expandable across Axial Spondyloarthritis, Chronic Low Back Pain, and Inflammatory Bowel Disease.